SHC2 and pancreatic adenocarcinoma: Additionally, the median values of SHC2, plasminogen activator, urokinase (PLAU) expression, MET expression, IL20RB expression, and riskscore were notably different in PAAD at outcomes CR relative to those at PR + PD + SD (P < 0.05, Figures 8L–P).